Notably the NF-κB-94 ins/del ATGG (rs28362491) polymorphism is linked to the increasing of the expression of NF-κB1 and NLRP3 identifying a potential therapeutic target in MPN neoplasms [73]. This evidence concerns the gene NFKB1 and myeloproliferative neoplasm.